Innovate Corp (STU:PST0)
€ 5.1 (0%) Market Cap: 143.36 Mil Enterprise Value: 671.92 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

Q2 2026 Innovate Corp Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT
Release Date Price: €5.1

Key Points

Positve
  • Innovate Corp (VATE) delivered a record second quarter at its infrastructure segment, DBMG, with revenue of $414 million and adjusted EBITDA of $48.7 million, driven by strong margin expansion and a 60 basis point improvement in gross margin to 18.5%.
  • Adjusted backlog at DBMG grew significantly to $2.7 billion, up from $1.8 billion at the end of 2025, providing strong revenue visibility into 2027 and 2028, supported by secular demand in data centers, AI, and advanced manufacturing.
  • The broadcasting segment completed a $105 million refinancing and entered a definitive agreement with Connex Corp, which is expected to acquire a 75% controlling interest, improving access to capital and allowing Innovate Corp (VATE) to retain a 25% stake with an option to increase to 40%.
  • Life sciences made progress at Metabeacon, with commercial engagement at over 100 healthcare institutions, CE mark approval in Europe, and ISO 13485 certification in China, advancing global commercialization and reimbursement initiatives.
  • Consolidated net income improved dramatically to $10.4 million, or $0.71 per share, compared to a net loss of $22 million in the prior year period, while total adjusted EBITDA rose to $46.3 million from $15.7 million.
  • R2 continued to expand its global footprint, securing registrations in Thailand and Malaysia, initiating testing in Korea, and building a backlog of approximately 110 systems, while reducing overhead through AI integration and a capital sales team.
Negative
  • Life sciences revenue decreased 31.3% year-over-year to $2.2 million, primarily due to lower R2 unit sales in North America and glacial spa units outside North America, driven by liquidity constraints.
  • The spectrum segment saw revenue decline by $300,000 to $5.4 million and adjusted EBITDA fall by $600,000 to $400,000, due to the termination of several networks and individual markets.
  • Consolidated cash and cash equivalents decreased to $87.8 million from $108.2 million at the end of 2025, with the non-operating corporate segment holding only $1.5 million in cash, down from $4.2 million.
  • Total principal indebtedness increased to $626.4 million from $617.5 million at the end of 2025, driven by PIK interest in non-operating and life sciences segments, adding financial pressure.
  • The broadcasting sale to Connex Corp is still pending FCC and regulatory approvals, creating uncertainty around the closing timeline and the extinguishment of the refinancing loan.
  • R2's revenue recognized during the quarter was only $2.2 million against total worldwide demand of 3.6 million, indicating a significant gap between demand and actual sales, partly due to liquidity constraints and the need for additional capital to support scaling.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VATE.N - Innovate Corp
Q2 2026 Innovate Corp Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Innovate Corps second quarter 2026 earnings conference call.

All participants will be in a listen-only mode.

Please note that this event is being recorded.

I would not like to turn the call over to Anthony Erasmus with Investor relations.

Please go ahead, sir.

Good afternoon.

Thank you for being with us to review Innovates second quarter 2026 earnings results.

We are joined today by Paul Voigt, Innovate's interim CEO, and Mike Senna, Innovate CFO.

We have posted our earnings release and our slide presentation on our website at innovatecorp.com.

We will begin our call with prepared remarks to be followed by a Q&A session.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot